Taho Pharmaceuticals (ROCO:6467) Other Current Payables: NT$20.38 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
33 GF Score
Price NT$110.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals Other Current Payables?

Taho Pharmaceuticals ROCO:6467 +6.25% 33 Other Current Payables is NT$20.38 Mil as of Dec. 2025. GuruFocus rates ROCO:6467 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Taho Pharmaceuticals's Other Current Payables for the quarter that ended in Dec. 2025 was NT$20.38 Mil.

Taho Pharmaceuticals's quarterly Other Current Payables declined from Dec. 2024 (NT$26.92 Mil) to Jun. 2025 (NT$5.77 Mil) but then increased from Jun. 2025 (NT$5.77 Mil) to Dec. 2025 (NT$20.38 Mil).

Taho Pharmaceuticals's annual Other Current Payables increased from Dec. 2023 (NT$22.66 Mil) to Dec. 2024 (NT$26.92 Mil) but then declined from Dec. 2024 (NT$26.92 Mil) to Dec. 2025 (NT$20.38 Mil).

Taho Pharmaceuticals Other Current Payables Related Terms

Taho Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals Other Current Payables Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only 9.78 8.35 22.66 26.92 20.38

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.66 7.18 26.92 5.77 20.38
ROCO:6467
33GF Score
Taho Pharmaceuticals Ltd ROCO:6467
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$20.38 Mil mean?
Taho Pharmaceuticals (ROCO:6467) has a Other Current Payables of NT$20.38 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Taho Pharmaceuticals and its competitors.
Is Taho Pharmaceuticals' Other Current Payables too high?
Taho Pharmaceuticals' current Other Current Payables is NT$20.38 Mil. Overall, Taho Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Other Current Payables compare to ZTS?
Taho Pharmaceuticals' Other Current Payables of NT$20.38 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Taho Pharmaceuticals and its competitors. Taho Pharmaceuticals's current Other Current Payables is NT$20.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Other Current Payables of NT$20.38 Mil. The current Other Current Payables is NT$20.38 Mil. Taho Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Other Current Payables is NT$20.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
33GF Score

Get the complete analysis for ROCO:6467

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$110.50
Price